A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 85
Healthy Volunteers: f
View:
• participants with preclinical AD
Locations
United States
Tennessee
K2 Medical Research
RECRUITING
Nashville
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2029-05
Participants
Target number of participants: 400
Treatments
Placebo_comparator: Placebo
Placebo
Experimental: Obicetrapib
10 mg Obicetrapib, once daily
Related Therapeutic Areas
Sponsors
Leads: NewAmsterdam Pharma